Acute Lymphoid Leukemia After Anti-TNF-alpha Treatment: A Case Report and Review of the Literature

The efficacy and safety of anti-tumor necrosis factor-alpha drugs have been shown in active ankylosing spondylitis cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that these drugs may cause some complications as reactivation of tuberculosis an...

Full description

Saved in:
Bibliographic Details
Published inArchives of rheumatology Vol. 30; no. 4; pp. 349 - 352
Main Authors Ozdemirkiran, Fusun Gediz, Payzin, Bahriye Kadriye, Coban, Eyup, Bayram, Korhan Baris, Kucukzeybek, Betul
Format Journal Article
LanguageEnglish
Published Istanbul Turkish League Against Rheumatism 01.12.2015
Prof Sebnem Ataman, President Turkish League Against Rheumatism
Subjects
Tumor necrosis factor
Online AccessGet full text

Cover

More Information
Summary:The efficacy and safety of anti-tumor necrosis factor-alpha drugs have been shown in active ankylosing spondylitis cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that these drugs may cause some complications as reactivation of tuberculosis and various hematologic malignancies. In this article, we report a 40-year-old male patient with ankylosing spondylitis who developed Philadelphia chromosome-positive acute lymphoid leukemia after treatment with tumor necrosis factor-alpha inhibitors. Keywords: Acute lymphoid leukemia; ankylosing spondylitis; anti-tumor necrosis factor-alpha drugs.
ISSN:2148-5046
1309-0291
1309-0283
DOI:10.5606/ArchRheumatol.2015.5669